Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

HeartSciences (HSCS) Free Cash Flow (2021 - 2026)

HeartSciences' Free Cash Flow history spans 6 years, with the latest figure at -$1.5 million for Q1 2026.

  • For Q1 2026, Free Cash Flow rose 10.31% year-over-year to -$1.5 million; the TTM value through Jan 2026 reached -$7.3 million, up 1.57%, while the annual FY2025 figure was -$7.4 million, 20.89% down from the prior year.
  • Free Cash Flow reached -$1.5 million in Q1 2026 per HSCS's latest filing, up from -$2.3 million in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of -$966278.0 in Q1 2022 to a low of -$2.3 million in Q4 2025.
  • Average Free Cash Flow over 5 years is -$1.6 million, with a median of -$1.6 million recorded in 2025.
  • Peak YoY movement for Free Cash Flow: crashed 153.52% in 2022, then grew 23.21% in 2025.
  • A 5-year view of Free Cash Flow shows it stood at -$1.1 million in 2022, then increased by 8.33% to -$990139.0 in 2023, then tumbled by 120.53% to -$2.2 million in 2024, then fell by 6.9% to -$2.3 million in 2025, then skyrocketed by 37.75% to -$1.5 million in 2026.
  • Per Business Quant, the three most recent readings for HSCS's Free Cash Flow are -$1.5 million (Q1 2026), -$2.3 million (Q4 2025), and -$2.0 million (Q3 2025).